Back to Authors

Kankeu Fonkoua, Lionel A

Mayo Clinic

Mayo Clinic, Rochester, MN.

Citations 4

Circulating Tumor DNA and Tissue Testing for Pancreatobiliary Tumors
Majeed, Umair , Patel, Jaydeepbhai, Ahmed, Ahmed , Elhariri, Ahmed , Albelal, Douaa , Rao, Nakka Naga Malleswara, Rachamala, Hari Krishnareddy, Mahadevan, Daruka , Ahn, Daniel H. , Halfdanarson, Thor R, Fonkoua, Lionel Aurelien Kankeu , Bekaii-Saab, Tanios S , Mody, Kabir , Babiker, Hani, Nakka, Naga Malleswara Rao , Ahmed, Ahmed K , Mosalem, Osama , Sonbol, Mohamad Bassam , Tran, Nguyen , Kankeu Fonkoua, Lionel A, Majeed, Umair , Mahadevia, Himil , Rao, Nakka Naga Malleswara, Rachamala, Hari Krishnareddy, Mukhopadhyay, Debabrata , Jones, Jeremy C , Borad, Mitesh J. , Tran, Nguyen, Mahipal, Amit , Wee, Wen , McWilliams, Robert R. , Bekaii‐Saab, Tanios

JAMA Network Open | September 12, 2025 | Volume: 8 | Issue: 9 | Pages: e2531373

10.1001/jamanetworkopen.2025.31373 Get It

Importance The prognosis of advanced pancreaticobiliary tumors is poor. Next-generation sequencing (NGS) of tissue samples is utilized to identify actionable alterations, but there are occasional limitations due to inadequate tissue acquisition. Circulating tumor DNA (ctDNA) is an alternative method, but its correlation with tissue-based NGS remains unexplored. Objectives To assess the mutation concordance (mCR) rates between ctDNA and tissue testing for patients with pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) and to evaluate how ctDNA performs as a treatment response biomarker. Design, Setting, and Participants This retrospective cohort study was conducted among patients with PDAC and CC treated at academic institutions from January 2014 to January 2025. Patients underwent ctDNA testing using 1 platform and tissue NGS testing using 2 platforms. Main Outcomes and Measures mCR, which measures the shared gene alterations observed by both ctDNA and tissue-based NGS testing, was calculated using the Spearman correlation for PDAC and CC. The performance of ctDNA as a treatment response biomarker was assessed by comparing serial ctDNA data with restaging scans and cancer antigen 19-9 levels in patients with PDAC. Results Our cohort included 790 patients: 570 with advanced PDAC (265 [46.5%] female; median [IQR] age, 64 [33-84] years) and 220 with advanced CC (95 [43.2%] female; median [IQR] age, 66 [42-88] years). Overall, 461 patients with PDAC (80.9%) and 192 patients with CC (87.2%) underwent ctDNA testing, while 239 patients with PDAC (41.9%) and 70 patients with CC (31.8%) had tissue NGS testing. Among patients with PDAC, 85 of 130 patients (65.4%) showed shared specific gene alterations between ctDNA and tissue testing; there was a significant mCR, with a Spearman correlation of 0.47 (95% CI, 0.28-0.62; P < .001). For patients with CC, 32 of 48 (66.7%) had shared alterations between ctDNA and tissue testing; there was a significant mCR, with a Spearman correlation of 0.56 (95% CI, 0.35-0.70; P < .001). A subgroup analysis of patients with PDAC who underwent serial ctDNA testing suggested that new TP53 subclones and increased ctDNA variant allele frequency levels of TP53 and KRAS were associated with higher odds of progressive disease (eg, increased TP53 frequency: odds ratio, 7.28; 95% CI, 2.15-24.66; P = .001). Conclusions and Relevance In this cohort study of patients with pancreaticobiliary tumors, there was a significant mCR between ctDNA and tissue NGS testing. Additionally, results suggest that ctDNA might detect resistant clones and enable assessment of treatment response.
Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications
Fonkoua, Lionel Aurelien Kankeu , Usón, Pedro Luiz Serrano , Mody, Kabir , Roberts, Lewis R. , Kankeu Fonkoua, Lionel A, Serrano Uson Junior, Pedro Luiz, Roberts, Lewis R , Uson, Pedro L S , Mahipal, Amit , Borad, Mitesh J.

Expert Opinion on Therapeutic Targets | January 17, 2022 | Volume: 26 | Issue: 1 | Pages: 79-92

10.1080/14728222.2022.2029412 Get It

Evaluating Unconscious Bias: Speaker Introductions at an International Oncology Conference
Duma, Narjust , Durani, Urshila , Woods, Cynthia , Fonkoua, Lionel Aurelien Kankeu , Wee, Christopher Eing , Fuentes, Harry E , González-Vélez, Miguel , Murphy, Martina, Marshall, Ariela L. , Knoll, Miriam A., Kankeu Fonkoua, Lionel A, Cook, Joselle M, Wee, Christopher, Fuentes, Harry E , Marshall, Ariela , Durani, Urshila , Cook, Joselle , Jain, Shikha , Graff, Stephanie L.

Journal of Clinical Oncology | October 11, 2019 | Volume: 37 | Issue: 36 | Pages: 3538-3545

10.1200/jco.19.01608 Get It

PURPOSE In a professional setting, the introduction of female speakers without their professional title may have an impact on the public’s perception of the female speaker. We examined how professional titles were used during speakers’ introductions at the ASCO Annual Meeting. METHODS We conducted a retrospective, observational study of video-archived speaker introductions at the 2017 and 2018 ASCO Annual Meetings. A “professional address” was defined as the professional title followed by the speaker’s full name or last name. Multivariable logistic regressions were used to identify factors associated with the form of address. RESULTS Of 2,511 videos reviewed, 781 met inclusion criteria. Female speakers were addressed less often by their professional title compared with male speakers (62% v 81%; P < .001). Males were less likely to use a professional address when introducing female speakers compared with females when introducing male speakers (53% v 80%; P < .01). When women performed speaker introductions, no gender differences in professional address were observed (75% v 82%; P = .13). Female speakers were more likely to be introduced by first name only (17% v 3%; P < .001). Male introducers were more likely to address female speakers by first name only compared with female introducers (24% v 7%; P < .01). In a multivariable regression including gender, degree, academic rank, and geographic location of the speaker’s institution, male speakers were more likely to receive a professional address compared with female speakers (odds ratio, 2.43; 95% CI, 1.71 to 3.47; P < .01). CONCLUSION When introduced by men, female speakers were less likely to receive a professional address and more likely to be introduced by first name only compared with their male peers.